##common.pageHeaderLogo.altText##

Review article: Medical guidelines

Vol. 150 No. 1718 (2020)

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland

  • Lorenzo A. Alberio
  • Anne Angelillo-Scherrer
  • Lars M. Asmis
  • Alessandro Casini
  • Pierre Fontana
  • Lukas Graf
  • Inga Hegemann
  • Johanna A. Kremer Hovinga
  • Wolfgang Korte
  • Thomas Lecompte
  • Martina Martinez
  • Michael Nagler
  • Jan-Dirk Studt
  • Dimitrios A. Tsakiris
  • Walter A. Wuillemin
  • members of the Working Party Hemostasis (WPH) of the Swiss Society of Hematology (SGH-SSH), in alphabetical order
Cite this as:
Swiss Med Wkly. 2020;150:w20210
Published
24.04.2020

Summary

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that occurs in 0.1–5% of heparin treated patients. Management of acute HIT currently involves (1) cessation of heparin exposure, and (2) inhibition of coagulation with an anticoagulant other than heparin. Several anticoagulants can be considered for the treatment of HIT. Anticoagulant monitoring, management of drug-induced adverse events including bleeding, and therapeutic dosing schedules in selected clinical settings represent challenges to the clinician treating HIT patients. Moreover, the fact that not all registered anticoagulants are approved for HIT in Switzerland further complicates the management of HIT. The present recommendations on the anticoagulant treatment of HIT in Switzerland have been elaborated by a panel of Swiss experts belonging to the Working Party Hemostasis (WPH) of the Swiss Society of Hematology (SGH-SSH). They are intended to support clinicians in their decision making when treating HIT patients.

References

  1. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, Suppl):e495S–530S. doi:.https://doi.org/10.1378/chest.11-2303
  2. Warkentin TE, Anderson JA. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128(3):348–59. doi:.https://doi.org/10.1182/blood-2016-01-635003
  3. Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127(5):546–57. doi:.https://doi.org/10.1182/blood-2015-07-661215
  4. Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E, et al. Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2014;166(5):774–82. doi:.https://doi.org/10.1111/bjh.12939
  5. Linkins LA, Bates SM, Lee AY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015;126(5):597–603. doi:.https://doi.org/10.1182/blood-2014-12-618165
  6. Nellen V, Sulzer I, Barizzi G, Lämmle B, Alberio L. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica. 2012;97(1):89–97. doi:.https://doi.org/10.3324/haematol.2011.048074
  7. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864–72. doi:.https://doi.org/10.1182/blood-2016-11-709873
  8. Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12(8):685–98. doi:.https://doi.org/10.1080/17474086.2019.1636645
  9. Warkentin TE, Climans TH, Morin PA. Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. N Engl J Med. 2018;378(19):1845–8. doi:.https://doi.org/10.1056/NEJMc1801799
  10. Pon TK, Mahajan A, Rosenberg A, Amin A, Shah D, Jenkins I, et al. Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2018;45(4):536–42. doi:.https://doi.org/10.1007/s11239-018-1646-x
  11. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286–92. doi:.https://doi.org/10.1056/NEJM200104263441704
  12. Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92. doi:.https://doi.org/10.1182/bloodadvances.2018024489
  13. Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104–13. doi:.https://doi.org/10.1182/blood-2017-04-778993
  14. Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252–61. doi:.https://doi.org/10.1056/NEJMcp1411910
  15. www.compendium.ch.
  16. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
  17. Borbe H, Müller J. Argatra Produktmonographie. Deutschland GmH: Mitsubishi Pharma; 2013.
  18. Tatsuno J, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805): Protein binding and blood cell binding. Jap Pharmacol Ther. 1986;14(suppl 5):243–9.
  19. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med. 1995;123(1):1–9. doi:.https://doi.org/10.7326/0003-4819-123-1-199507010-00001
  20. Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs. 2002;62(15):2283–314. doi:.https://doi.org/10.2165/00003495-200262150-00016
  21. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012;129(4):407–17. doi:.https://doi.org/10.1016/j.thromres.2011.10.037
  22. Shepherd MF, Jacobsen JM, Rosborough TK. Argatroban therapy using enzymatic anti-factor IIa monitoring. Ann Pharmacother. 2011;45(3):422–3. doi:.https://doi.org/10.1345/aph.1P274
  23. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al.; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838–43. doi:.https://doi.org/10.1161/01.CIR.103.14.1838
  24. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG ; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849–56. doi:.https://doi.org/10.1001/archinte.163.15.1849
  25. Colucci G, Nagler M, Klaus N, Conte T, Giabbani E, Alberio L. Practical guidelines for Argatroban and Bivalirudin in patients with Heparin-induced Thrombocytopenia. J Transl Sci. 2015;1(2):37–42. doi:.https://doi.org/10.15761/JTS.1000109
  26. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006;26(4):452–60. doi:.https://doi.org/10.1592/phco.26.4.452
  27. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother. 2002;36(6):1028–41. doi:.https://doi.org/10.1345/aph.1A197
  28. Pistulli R, Oberle V, Figulla HR, Yilmaz A, Pfeifer R. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Blood Coagul Fibrinolysis. 2011;22(1):76–8. doi:.https://doi.org/10.1097/MBC.0b013e328340ff24
  29. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging. 2007;24(6):489–99. doi:.https://doi.org/10.2165/00002512-200724060-00005
  30. Skrupky LP, Smith JR, Deal EN, Arnold H, Hollands JM, Martinez EJ, et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2010;30(12):1229–38. doi:.https://doi.org/10.1592/phco.30.12.1229
  31. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest. 2006;129(5):1167–75. doi:.https://doi.org/10.1378/chest.129.5.1167
  32. Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004;66(6):2446–53. doi:.https://doi.org/10.1111/j.1523-1755.2004.66022.x
  33. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20(3):318–29. doi:.https://doi.org/10.1592/phco.20.4.318.34881
  34. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6, Suppl):844S–86S. doi:.https://doi.org/10.1378/chest.08-0761
  35. Fogerty AE. Challenges of Anticoagulation Therapy in Pregnancy. Curr Treat Options Cardiovasc Med. 2017;19(10):76. doi:.https://doi.org/10.1007/s11936-017-0575-x
  36. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost. 2002;28(5):439–46. doi:.https://doi.org/10.1055/s-2002-35284
  37. Lewis B, Hursting M. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A, editors. Heparin-induced thrombocytopenia. New York, Basel: Marcel Dekker; 2006.
  38. Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel Y, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care. 2015;19(1):396. doi:.https://doi.org/10.1186/s13054-015-1109-0
  39. Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood Coagul Fibrinolysis. 2008;19(4):288–93. doi:.https://doi.org/10.1097/MBC.0b013e3282fe73ec
  40. Zhang L, Yang J, Zheng X, Fan Q, Zhang Z. Influences of argatroban on five fibrinogen assays. Int J Lab Hematol. 2017;39(6):641–4. doi:.https://doi.org/10.1111/ijlh.12719
  41. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209–18. doi:.https://doi.org/10.1182/blood-2011-11-376293
  42. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001;85(3):435–40. doi:.https://doi.org/10.1055/s-0037-1615601
  43. Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014;13(1):25–43. doi:.https://doi.org/10.1517/14740338.2013.823946
  44. https://ec.europa.eu/health/documents/community-register/2017/20170914138919/anx_138919_de.pdf.
  45. https://www.accord-healthcare.de/sites/default/files/2018-06/FI_Bivalirudin_Stand%20102016.pdf.
  46. Vo QA, Lin JK, Tong LM. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia. Ann Pharmacother. 2015;49(2):178–84. doi:.https://doi.org/10.1177/1060028014562949
  47. Bartholomew JR. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 4th edition. London, UK: Informa Healthcare; 2007. p. 409–39.
  48. Koster A, Chew D, Gründel M, Bauer M, Kuppe H, Spiess BD. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003;96(2):383–6. doi:.https://doi.org/10.1213/00000539-200302000-00015
  49. Stiekema JC, Wijnand HP, Van Dinther TG, Moelker HC, Dawes J, Vinchenzo A, et al. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol. 1989;27(1):39–48. doi:.https://doi.org/10.1111/j.1365-2125.1989.tb05333.x
  50. Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, et al. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. J Am Coll Cardiol. 2017;70(21):2636–48. doi:.https://doi.org/10.1016/j.jacc.2017.09.1099
  51. Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. Res Pract Thromb Haemost. 2018;2(4):678–83. doi:.https://doi.org/10.1002/rth2.12145
  52. Kreimann M, Brandt S, Krauel K, Block S, Helm CA, Weitschies W, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood. 2014;124(15):2442–9. doi:.https://doi.org/10.1182/blood-2014-03-559518
  53. Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol. 2010;3(5):567–81. doi:.https://doi.org/10.1586/ehm.10.54
  54. D’Angelo A, Valle PD, Fattorini A, Luciano C. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia. Thromb Haemost. 2006;95(3):573–5. doi:.https://doi.org/10.1160/TH05-11-0722
  55. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99(1):208–14. doi:.https://doi.org/10.1160/TH07-04-0252
  56. Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791–6. doi:.https://doi.org/10.1182/blood-2005-05-1938
  57. www.pathology.med.umich.edu.
  58. Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost. 2004;2(2):346–8. doi:.https://doi.org/10.1111/j.1538-7933.2004.0584a.x
  59. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, Suppl):e24S–43S. doi:.https://doi.org/10.1378/chest.11-2291
  60. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106(20):2550–4. doi:.https://doi.org/10.1161/01.CIR.0000038501.87442.02
  61. Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers JC, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004;124(5):653–8. doi:.https://doi.org/10.1111/j.1365-2141.2003.04811.x
  62. Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016;14(6):1206–10. doi:.https://doi.org/10.1111/jth.13330
  63. Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(4):607–9. doi:.https://doi.org/10.1016/j.thromres.2015.01.009
  64. Davis KA, Davis DO. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia. Eur J Haematol. 2017;99(4):332–5. doi:.https://doi.org/10.1111/ejh.12921
  65. Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. Thromb Haemost. 2016;116(2):397–400. doi:.https://doi.org/10.1160/TH16-02-0101
  66. Barlow A, Barlow B, Reinaker T, Harris J. Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia. Pharmacotherapy. 2019;39(8):837–53. doi:.https://doi.org/10.1002/phar.2298
  67. Rogers KC, Finks SW. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Am J Med. 2019;132(1):38–41. doi:.https://doi.org/10.1016/j.amjmed.2018.06.028
  68. Information for healthcare professionals for Ondexxyan http://www.ondexxya.eu/downloads/pdf/anx_144471_en.pdf.
  69. Ollier E, Hodin S, Lanoiselée J, Escal J, Accassat S, De Magalhaes E, et al. Effect of Activated Charcoal on Rivaroxaban Complex Absorption. Clin Pharmacokinet. 2017;56(7):793–801. doi:.https://doi.org/10.1007/s40262-016-0485-1
  70. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24(10):2757–65. doi:.https://doi.org/10.1185/03007990802361499
  71. Sauter TC, Eberle B, Wuillemin WA, Thiele T, Angelillo-Scherrer A, Exadaktylos AK, et al. How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Med Wkly. 2018;148:w14598. doi:.https://doi.org/10.4414/smw.2018.14598
  72. Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017;130(15):1706–12. doi:.https://doi.org/10.1182/blood-2017-05-782060
  73. Joseph J, Rabbolini D, Enjeti AK, Favaloro E, Kopp MC, McRae S, et al. Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group. Med J Aust. 2019;210(11):509–16. doi:.https://doi.org/10.5694/mja2.50213
  74. Chong BH, Magnani HN. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 4th edition. London, UK: Informa Healthcare; 2007.
  75. Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 4th edition. London, UK: Informa Healthcare; 2007. p. 463–85.
  76. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39(2):231–6. doi:.https://doi.org/10.1345/aph.1E480
  77. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 4th edition. Boca Raton, Florida: CRC Press; 2007. p. 379–408.
  78. Jang IK, Lewis BE, Matthai WH, Jr, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis. 2004;18(1):31–7. doi:.https://doi.org/10.1007/s11239-004-0171-2
  79. Lewis BE, Matthai WH, Jr, Cohen M, Moses JW, Hursting MJ, Leya F ; ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57(2):177–84. doi:.https://doi.org/10.1002/ccd.10276
  80. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007;35(4):1165–76. doi:.https://doi.org/10.1097/01.CCM.0000259538.02375.A5
  81. Beiderlinden M, Treschan T, Görlinger K, Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs. 2007;31(6):461–5. doi:.https://doi.org/10.1111/j.1525-1594.2007.00388.x
  82. Kleinschmidt S, Stephan B, Pindur G, Bauer C. Argatroban: Pharmakologische Eigenschaften und anästhesiologische Aspekte [Argatroban: pharmacological properties and anaesthesiological aspects]. Anaesthesist. 2006;55(4):443–50. doi:.https://doi.org/10.1007/s00101-005-0962-7
  83. Koster A, Spiess B, Jurmann M, Dyke CM, Smedira NG, Aronson S, et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the “EVOLUTION OFF” trial. Anesth Analg. 2006;103(3):540–4. doi:.https://doi.org/10.1213/01.ane.0000226098.95698.0f
  84. Spiess BD. Update on heparin-induced thrombocytopenia and cardiovascular interventions. Semin Hematol. 2005;42(3, Suppl 3):S22–7. doi:.https://doi.org/10.1053/j.seminhematol.2005.05.014
  85. Spiess BD, DeAnda A, McCarthy HL, Yeatman D, Katlaps G, Cooper C, et al. Case 1-2006: off-pump coronary artery bypass graft surgery anticoagulation with bivalirudin: a patient with heparin-induced thrombocytopenia syndrome type II and renal failure. J Cardiothorac Vasc Anesth. 2006;20(1):106–11. doi:.https://doi.org/10.1053/j.jvca.2005.11.011
  86. Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL, 2nd, Aronson S, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83(2):572–7. doi:.https://doi.org/10.1016/j.athoracsur.2006.09.038
  87. Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA, Jr. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg. 2002;74(6):2177–9. doi:.https://doi.org/10.1016/S0003-4975(02)04125-5